home / stock / prog / prog quote
Last: | $0.8845 |
---|---|
Change Percent: | -3.47% |
Open: | $0.9005 |
Close: | $0.8845 |
High: | $0.92 |
Low: | $0.84 |
Volume: | 2,720,100 |
Last Trade Date Time: | 05/06/2022 04:54:39 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8845 | $0.9005 | $0.8845 | $0.92 | $0.84 | 2,720,100 | 05-06-2022 |
$0.9163 | $0.9709 | $0.9163 | $0.9796 | $0.8831 | 3,179,865 | 05-05-2022 |
$0.9743 | $0.8557 | $0.9743 | $1.01 | $0.825 | 8,056,586 | 05-04-2022 |
$0.8578 | $0.85 | $0.8578 | $0.87 | $0.82 | 2,256,826 | 05-03-2022 |
$0.842 | $0.8746 | $0.842 | $0.8746 | $0.79 | 3,559,895 | 05-02-2022 |
$0.8372 | $0.8322 | $0.8372 | $0.92 | $0.8239 | 1,848,188 | 04-29-2022 |
$0.853 | $0.875 | $0.853 | $0.88 | $0.785 | 3,234,062 | 04-28-2022 |
$0.8575 | $0.8792 | $0.8575 | $0.92 | $0.8501 | 2,661,940 | 04-27-2022 |
$0.9023 | $1 | $0.9023 | $1.01 | $0.9 | 3,868,978 | 04-26-2022 |
$0.9933 | $0.95 | $0.9933 | $1.01 | $0.9309 | 2,539,239 | 04-25-2022 |
$0.9619 | $0.971 | $0.9619 | $1.01 | $0.9346 | 2,651,323 | 04-22-2022 |
$0.9801 | $1.02 | $0.9801 | $1.06 | $0.9759 | 3,218,112 | 04-21-2022 |
$1.02 | $0.982 | $1.02 | $1.06 | $0.96 | 4,023,700 | 04-20-2022 |
$1.01 | $0.99 | $1.01 | $1.02 | $0.9522 | 4,486,980 | 04-19-2022 |
$0.9916 | $1.02 | $0.9916 | $1.02 | $0.9509 | 5,312,385 | 04-18-2022 |
$1 | $1.05 | $1 | $1.05 | $1 | 3,417,461 | 04-15-2022 |
$1 | $1.05 | $1 | $1.05 | $1 | 3,198,151 | 04-14-2022 |
$1.05 | $1.03 | $1.05 | $1.06 | $1 | 4,737,186 | 04-13-2022 |
$1.03 | $1.11 | $1.03 | $1.15 | $1 | 6,954,181 | 04-12-2022 |
$1.09 | $1.14 | $1.09 | $1.14 | $1.08 | 6,372,495 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Progenity Inc. Company Name:
PROG Stock Symbol:
NASDAQ Market:
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeu...
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial ...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s ...